LUPIN
₹756.95
Revenue | ₹4160.46Cr |
Net Profits | ₹129.73Cr |
Net Profit Margins | 3.12% |
Lupin Ltd’s revenue fell -0.09% since last year same period to ₹4160.46Cr in the Q2 2022-2023. On a quarterly growth basis, Lupin Ltd has generated 10.96% jump in its revenue since last 3-months.
Lupin Ltd’s net profit jumped 106.18% since last year same period to ₹129.73Cr in the Q2 2022-2023. On a quarterly growth basis, Lupin Ltd has generated 245.63% jump in its net profits since last 3-months.
Lupin Ltd’s net profit margin jumped 106.19% since last year same period to 3.12% in the Q2 2022-2023. On a quarterly growth basis, Lupin Ltd has generated 231.24% jump in its net profit margins since last 3-months.
Earning Per Share (EPS) | 1.5 |
Return on Equity (ROE) | -1.2 |
Dividend Per Share (DPS) | 4 |
Lupin Ltd’s earning per share (EPS) jumped 110.39% since last year same period to 1.5 in the Q2 2022-2023. This indicates that the Lupin Ltd has generated 110.39% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Lupin Ltd’s return on equity (ROE) stands at -1.2.
Lupin Ltd declared 4 dividend per share during the results announcement for Q1 2022-2023.
Organisation | Lupin Ltd |
Headquarters | Mumbai |
Industry | Pharmaceuticals |
Indian stocks brokerage services are provided by INDmoney Private Limited. INDmoney Private Limited is carrying out the business of in respect to stock broking activities and also carries out the activities of depository participant. SEBI Registration No. INZ000305337 | SEBI Depository Participant Registration No. IN-DP-690-2022 Depository Participant ID: CDSL 12095500 | Trading and Clearing Member of NSE (90267, M70042) and BSE (6779)
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. The securities quoted are exemplary and not recommendatory. Past performance is not indicative of future returns.